Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 7:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Prophylactic Antibiotic Administration for Bladder OnabotulinumtoxinA Injection

NCT05719285
Conditions
Overactive Bladder, Overactive Bladder Syndrome, Urge Incontinence, Urinary Incontinence, Urge
Interventions
Single-Dose Antibiotic, Multi-Dose Antibiotic
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Infection, Bone Neoplasms
Interventions
24-Hour Prophylactic Cefazolin* Antibiotic Regimen, 5-Days Prophylactic Cefazolin* Antibiotic Regimen
Drug
Lead sponsor
McMaster University
Other
Eligibility
12 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
34
States / cities
Little Rock, Arkansas • Los Angeles, California • Redwood City, California + 26 more
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Conditions
COVID-19 Pneumonia, Impaired Respiratory Function
Interventions
MAS825, Placebo, Standard of Care (SoC)
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Chula Vista, California • Glendale, California • Irvine, California + 17 more
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Conditions
Dental Caries
Interventions
C16G2, Placebo
Drug · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
5
States / cities
Indianapolis, Indiana • Kalispell, Montana • New York, New York + 2 more
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
FMP30 Donor Stool, Fecal Microbiota Transplantation (FMT) of FMP30 Donor Stool, Observational Control
Drug · Procedure · Other
Lead sponsor
Jeffrey Gelfand
Other
Eligibility
18 Years to 60 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
San Francisco, California
Conditions
Obesity in Pregnancy, Labor Complication
Interventions
Azithromycin, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Conditions
Surgical Site Infection, Breast Reconstruction, Antibiotic Use
Interventions
Single pre-operative dose of intravenous antibiotics with intraoperative redosing, One week of post-operative antibiotics
Drug
Lead sponsor
The Plastic Surgery Foundation
Other
Eligibility
18 Years and older · Female only
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Chicago, Illinois • Baltimore, Maryland • Ann Arbor, Michigan + 2 more
Conditions
Bone Infection, Joint Infection, Bone and Joint Infection
Interventions
Omadacycline Pill, Standard of Care
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Torrance, California
Conditions
AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category), MDS (Myelodysplastic Syndrome), CML (Chronic Myelogenous Leukemia), CLL (Chronic Lymphocytic Leukemia), Prolymphocyctic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasm (MPN), Lymphoma, Myelofibrosis
Interventions
Conditioning Regimen A, Conditioning Regimen B, Conditioning Regimen C, Conditioning Regimen D, Conditioning Regimen E, Hematopoietic Cell Transplantation, PTCy (50 mg/kg D3, D4), PTCy (25 mg/kg D3, D4), Post-transplant Tacrolimus, Post-transplant Mycophenolate mofetil, Post-transplant Abatacept, Post-transplant Ruxolitinib, Supportive Care: Growth Factors, Supportive Care: Blood Products, Supportive Care: Infection Prophylaxis, Supportive Care: Intravenous immune globulin (IVIG), Supportive Care: Seizure prophylaxis, Supportive Care: Monitoring and management of CRS, Supportive Care: Prophylaxis against infections, Supportive Care: Prophylaxis against infections, Supportive Care: Lipid elevations, Study treatment compliance, Prohibited Concomitant Therapy, Permitted Concomitant Therapy
Drug · Procedure · Other
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
18 Years to 66 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
13
States / cities
Birmingham, Alabama • Duarte, California • Palo Alto, California + 10 more
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Nu-3 Topical Gel for Treatment of Diabetic Foot Ulcer

NCT05276401
Conditions
Chronic Diabetic Foot Ulcers
Interventions
5% Bisphosphocin Topical Gel, Placebo Topical Gel, 10% Bisphosphocin Topical Gel
Drug
Lead sponsor
Lakewood-Amedex Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Jonesboro, Arkansas • Fresno, California • South Miami, Florida + 2 more
Withdrawn Not applicable Interventional Accepts healthy volunteers

Treatment of Chorioamnionitis After Delivery

NCT00814905
Conditions
Chorioamnionitis
Interventions
saline, ampicillin gentamicin, ampicillin gentamicin clindamycin
Drug
Lead sponsor
United States Naval Medical Center, Portsmouth
Federal
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Portsmouth, Virginia
Conditions
Urinary Tract Infection
Interventions
Fosfomycin tromethamine, Levofloxacin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Sylmar, California • Torrance, California • Decatur, Georgia + 9 more
Conditions
Gonorrhoea
Interventions
Cefixime
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
Drug
Lead sponsor
Pfizer
Industry
Eligibility
Up to 39 Weeks
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Conditions
Multi-Drug Resistant Organism Colonization
Interventions
Allogeneic Microbiota in Glycerol (9%) (AMG)
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Atlanta, Georgia • Decatur, Georgia • Hinsdale, Illinois + 1 more
Terminated Phase 4 Interventional Results available

Avoiding Neuromuscular Blockers to Reduce Complications

NCT03962725
Conditions
Respiratory Failure, Respiratory Infection, Aspiration Pneumonia, Pneumonitis, Atelectasis, Bronchospasm
Interventions
Neuromuscular Blocking Agents, Anesthetic Adjuncts
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
Interventions
MEK162, MEK inhibitor; oral, Physician's choice chemotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
77
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 37 more
Not yet recruiting Phase 2Phase 3 Interventional

IO Vancomycin Spine

NCT06748144
Conditions
Lumbar Fusion Surgery
Interventions
Intraosseous Vancomycin, Intravenous Vancomycin
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Bacterial Infections, Intra-Abdominal Infection, Pneumonia, Bacterial, Skin Diseases, Bacterial, Skin Diseases, Infectious
Interventions
Tygacil
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
8 Years to 11 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
18
States / cities
Long Beach, California • Oakland, California • Orange, California + 15 more